Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

Astellas Pharma Inc. (ALPMY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...

Astellas Pharma Inc. (ALPMY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company ...

Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...

Thank you very much for joining our FY 2024 Financial Results Announcement Meeting by Astellas Pharma Inc. out of your very busy schedule today. I'm delighted to serve as a moderator. I'm Ikeda ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.80%, which has investors questioning if this is right time ...